CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
12 nov. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
11 nov. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
30 août 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
08 août 2024 08h23 HE
|
CG Oncology Inc.
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
18 juin 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
06 juin 2024 12h14 HE
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
24 mai 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
09 mai 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
03 mai 2024 11h23 HE
|
CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
26 avr. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024